Piflufolastat F-18 (<sup>18</sup>F-DCFPyL) for PSMA PET imaging in prostate cancer 

202230 citationsJournal Article

Authors

Andrew F. Voter · Johns Hopkins University

Rudolf A. Werner · Universitätsklinikum Würzburg

Kenneth J. Pienta · Johns Hopkins Medicine

Michael A. Gorin · University of Pittsburgh

Martin G. Pomper · Sidney Kimmel Comprehensive Cancer Center

Lilja B. Sólnes · Sidney Kimmel Comprehensive Cancer Center

Steven P. Rowe

Abstract

The OSPREY and CONDOR clinical trials have demonstrated the superiority of <sup>18</sup>F-DCFPyL over conventional imaging modalities for the staging and restaging of prostate cancer. The remarkable diagnostic accuracy of PSMA-PET is reshaping prostate cancer imaging and the modularity of these agents hint at exciting new diagnostic and therapeutic opportunities that have the potential to improve the care of patients with prostate cancer as a whole. .

Topics & Keywords

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Prostate Cancer Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Expert Review of Anticancer Therapy

Volume 22, Issue 7, pp. 681-694

DOI: 10.1080/14737140.2022.2081155

Field-Weighted Citation Impact: 4.25

Command Palette

Piflufolastat F-18 (<sup>18</sup>F-DCFPyL) for PSMA PET imaging in prostate cancer

Authors

Abstract

Topics & Keywords

UN Sustainable Development Goals

Publication Details

Piflufolastat F-18 (<sup>18</sup>F-DCFPyL) for PSMA PET imaging in prostate cancer 